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Abstract
Background: Despite substantial progress, pathogenesis and therapy of chronic pain are still the focus of many
investigations. The ATP-gated P2X7 receptor (P2X7R) has previously been shown to play a central role in animal
models of nociceptive inflammatory and neuropathic pain. Recently, we found that the adaptive immune system
is involved in the pathophysiology of chronic nociceptive and neuropathic pain in humans. So far, data regarding
P2X7R expression patterns on cells of the adaptive immune system of pain patients are scarce. We therefore
analyzed the P2X7R expression on peripheral blood lymphocytes and monocytes, as well as serum levels of IL-1β
in patients suffering from chronic nociceptive and neuropathic pain in comparison to healthy volunteers in order to
identify individuals who might benefit from a P2X7R modulating therapy.
Methods: P2X7R messenger RNA (mRNA) and protein expression were determined in patients with either chronic
nociceptive low back pain (CLBP) or neuropathic pain (NeP), and in healthy volunteers by quantitative real-time PCR
(qPCR) and by fluorescence-assisted cell-sorting (FACS), respectively. IL-1β serum levels were measured with a
multiplex cytokine assay.
Results: Compared to healthy volunteers, P2X7R mRNA (1.6-fold, p = 0.038) and protein levels were significantly
increased on monocytes (NeP: 24.6 ± 6.2, healthy volunteers: 17.0 ± 5.4; p = 0.002) and lymphocytes (NeP: 21.8 ± 6.5,
healthy volunteers: 15.6 ± 5.2; p = 0.009) of patients with NeP, but not in patients with CLBP. Similarly, IL-1β serum
concentrations were significantly elevated only in NeP patients (1.4-fold, p = 0.04).
Conclusions: A significant upregulation of P2X7R and increased IL-1β release seems to be a particular
phenomenon in patients with NeP. P2X7R inhibitors may therefore represent a potential option for the treatment
of this frequently intractable type of pain.
German Clinical Trial Register (DRKS): Registration Trial DRKS00005954.
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Background
Purinergic P2X receptors (P2XRs) are ATP-gated cation
channels, divided into seven subtypes (P2XR1-P2XR7).
They are predominantly expressed on cells of the
hematopoietic lineage including macrophages, micro-
glia, and lymphocyte subtypes [1].
The subtype receptor P2X7R has been found to play
a major role in central nervous system (CNS) processes,
including neurodegeneration, traumatic brain injuries,
psychiatric disorders, and pain. The exceptional role of
P2X7R in pain syndromes has been shown in various
animal models of nociceptive inflammatory and neuro-
pathic pain [2–5]. In humans, P2X7R messenger RNA
(mRNA) expression was shown to be increased in leu-
kocytes of patients with chronic fatigue syndrome [6].
Results of experimental P2X7R inhibition in a rat model
of inflammatory arthritis, induced by injection of Freund’s
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complete adjuvant into one hind paw, were promising [7].
Furthermore, P2X7R antagonists have been tested in clin-
ical trials in patients with rheumatoid arthritis [8, 9].
P2X7R activation leads to a rapid increase in intracellular
calcium concentrations and triggers the release of the pro-
inflammatory and pro-nociceptive cytokine IL-1β [10]. IL-
1β is known to be a key mediator in neurodegeneration,
chronic inflammation, and chronic pain by affecting neur-
onal cell death [1, 10]. Pharmacological inhibition of IL-1β
attenuates hyperalgesia induced by spinal cord inflamma-
tion in rats [11]. Moreover, higher serum levels of IL-1β
have been implicated in the pathogenesis of depression
[12, 13]. Accordingly, P2X7R inhibitors displayed an anti-
depressant activity in mice [14]. P2X7R has been found to
be readily expressed on the cell surface of both microglia
and immune cells, suggesting a link between the CNS
and the immune system [1, 15]. Since the adaptive im-
mune system is critically involved in the pathophysiology
of chronic pain [16], we systematically investigated the ex-
pression of P2X7R on lymphocytes and monocytes of pa-
tients suffering from either chronic low back pain (CLBP)
or chronic neuropathic pain (NeP) in comparison to
healthy volunteers. We analyzed P2X7R protein by flow
cytometry (FACS) and determined P2RX7 mRNA expres-
sion by real-time PCR (qPCR). Furthermore, we analyzed
the expression of the cytokine IL-1β.
Methods
Ethics statement
The study followed the principles of the Declaration of
Helsinki, was approved by the Ethics Committee of the
LMU Munich, and has been registered by the German
Clinical Trial Register (Registration Trial DRKS00005954).
Subjects
Subject recruitment was estimated for 2 years. Patients
presenting to our Department of Pain Medicine with
chronic pain who met the inclusion criteria, as well as
healthy volunteers, were enrolled after written informed
consent.
Inclusion criteria
Patients suffering from chronic non-specific low back pain
(CLBP) without any signs of neuropathic pain compo-
nents and patients suffering from neuropathic pain (NeP)
were included. CLBP was defined as persistent low back
pain not attributable to a detectable pathology (e.g. infec-
tion, tumor, osteoporosis, trauma, inflammatory disorder,
or radicular syndrome). NeP was diagnosed according to
its international definition (“pain caused by a lesion or dis-
ease of the somatosensory nervous system”). All patients
were assessed by detailed pain history, physical examin-
ation, and the PainDETECT-questionnaire. This question-
naire consists of several items related to neuropathic pain
symptoms (burning sensations, tingling or prickling sensa-
tions, shooting/lancinating, hyperalgesia, dysesthesia, allo-
dynia, or paresthesia) with excellent sensitivity (85 %) and
specificity (80 %) [17]. Healthy volunteers were evaluated
for any history of pain. If no history of pain was detected
in these individuals, they were included in the study.
Exclusion criteria
Exclusion criteria were autoimmune, chronic systemic,
inflammatory, neoplastic, or psychiatric diseases, drug
abuse, and pregnancy. Patients on irregular medication
with opioids, non-opioids, or co-analgesics were ex-
cluded. None of the patients had been treated with cor-
ticosteroids or had received immunomodulatory agents
before or during the study. Any acute inflammatory
process was ruled out by laboratory testing including
serum concentration of C-reactive protein (CRP) and
total and differential leukocyte count as well as meas-
urement of the body temperature. Patients with mixed
pain (nociceptive and neuropathic components), e.g.,
low back pain with radiculopathy, were excluded.
Assessment of pain, stress, and depressive
symptomatology
Patients rated their recalled average pain intensity both
at rest and while moving using an 11-point numerical
rating scale (NRS): 0 meaning “no pain” and 10 mean-
ing “worst pain imaginable.” Self-perceived stress was
evaluated using the German version of the Question-
naire for Actual Demands (“KAB”: “Kurzfragebogen zur
aktuellen Beanspruchung”) in patients and in healthy
volunteers. The KAB was designed to repeatedly quan-
tify the individual’s level of acute or chronic stress. It is
highly sensitive to short-term or situational changes
during a stressful experience [18]. The rating on a scale
ranging from 1 to 6 is based on normalized adjectives.
Higher KAB values indicate the perception of increased
stress levels. The center for epidemiologic studies de-
pression scale (CES-D scale) which measures depressive
symptomatology in the general population was used to
assess depressive symptomatology in patients and in
healthy volunteers. This scale contains 20 items to ex-
plore feelings or experiences during the past week.
These 20 items belong to 4 main categories: depressed
affect, positive affect, somatic complaints/retarded ac-
tivity, and interpersonal experiences. Response options
range from 0 to 3 for each item (0 = rarely or never, 1 =
some or little of the time, 2 = moderately or much of
the time, 3 = most or almost all of the time). Results
range from 0 to 60, with higher values representing
more depressive symptoms. Values >25 are considered
pathological [19].
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Leukocyte count and cytokine assessment
Peripheral blood was collected from patients and healthy
volunteers between 9:00 and 9:30 AM. Samples were
assessed for differential leukocyte count by routine labora-
tory testing. For cytokine assessment, blood was centri-
fuged at 2000×g for 10 min to obtain cell-free serum.
After centrifugation, supernatants were harvested and
frozen at −80 °C until further use. IL-1β serum concentra-
tions were determined using a human cytokine immuno-
assay (Myriad Rules-Based Medicine Inc., Austin, Texas,
USA). The microbead assay is based on a Luminex tech-
nology and quantifies protein in a similar manner to
standard sandwich ELISA techniques, with comparable
sensitivity and range [20].
Flow cytometric staining and analysis
Peripheral blood mononuclear cells (PBMCs) from
heparinized venous blood samples were separated by
Ficoll density gradient centrifugation (Sigma Aldrich,
Taufkirchen, Germany). PBMCs were then cryopre-
served in RPMI freezing media containing 10 % FCS
and 10 % DMSO, frozen at −30 °C for 24 h, and then
stored at −196 °C [21]. For FACS analyses, samples
were thawed rapidly and washed twice with ice-cold
FACS buffer (HBSS containing 1 % BSA and 0.1 %
NaN3) to eliminate any remaining DMSO. For extra-
cellular staining, cells were co-incubated with PerCP-
labeled antihuman CD4 antibody (1:50, Biolegend, San
Diego, CA, USA) and FITC-labeled antihuman P2X7R
antibody (1:100, Alomone Labs, Jerusalem, Israel) at
room temperature for 1 hour. Again, cells were washed
twice with FACS buffer (400×g, 5 min, 4 °C) to remove
excessive antibodies. P2X7R expression was then ana-
lyzed with an Attune Acoustic Focusing Cytometer
(Life Technologies, Carlsbad, USA) as described by
Gudipaty et al. [22]. Representative density plots and
gating strategy are displayed in Fig. 1; representative
histograms for evaluation of CD4+/CD4− cells and for
analyses of mean fluorescence intensity (MFI) are
shown in Fig. 2.
Quantitative RT-PCR
CD4+ cells were isolated from PBMCs by magnetic bead
separation with the Whole Blood CD4 MicroBeads kit
(MACS Miltenyi Biotec, Auburn, CA, USA) according to
the manufacturer’s recommendations. Subsequently, total
RNA was isolated with the mirVana miRNA Isolation Kit,
followed by a DNase digest with the Turbo DNA-free kit
(Ambion). Quantity and purity of the isolated RNA were
measured with a NanoDrop ND-1000 spectrophotometer
(Peqlab). After the amplification of total RNA using the
TargetAmp 1-Round aRNA Amplification Kit (Epicentre
Biotechnologies, Madison, WI, USA) and purification
using an RNeasy Mini Kit (Qiagen), cDNA synthesis was
performed with the SuperScript III First Strand Synthesis
System (Invitrogen) and oligo-dT and random hexamer
primers (Qiagen). Quantitative RT-PCR was performed in
duplicates with a LightCycler 480 instrument (Roche
Diagnostics, Mannheim, Germany) using LightCycler 480
Probes Master and RealTime Ready Single Assays (Roche
Diagnostics). Cycling conditions were as follows: 95 °C for
10 min, 45 cycles at 95 °C for 10 s, 60 °C for 30 s, and 72 °
C for 15 s. Relative mRNA expression of P2RX7 was cal-
culated by the Relative Quantification Software (Roche
Diagnostics) using an efficiency-corrected algorithm with
standard curves and reference gene normalization against
the reference genes succinate dehydrogenase complex
subunit A (SDHA) and TATA box binding protein (TBP)
as described previously [23]. Primer sequences and assay
characteristics are given in Table 1.
Data analyses
Statistical analyses were performed with SigmaStat 12.0
(Systat Software, Chicago, USA). Every statistical analysis
was started with testing for normal distribution using





Fig. 1 Gating strategy for the detection of lymphocytes, monocytes, CD4+ and CD4− cells, lymphocytes (LC), and monocytes (MC) was gated according
to forward scatter (FSC) and side scatter (SSC) characteristics; PerCP-labeled antihuman CD4 antibody was used to separate CD4+/CD4− cells
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tested with the t test for results with normal distribution
and the nonparametric Mann-Whitney Rank Sum Test
for all data without normal distribution. Discrete variables
were compared with the Fisher’s exact test. In order to de-
termine significant differences between pain syndromes,
we used a one-way ANOVA tests and multiple com-
parisons versus a control group (Holm-Sidak method).
p values <0.05 were considered statistically significant. All
results are expressed as mean ± standard deviation (SD).
Results
Subjects
Within 2 years of recruitment, 19 patients suffering from
CLBP and 19 patients suffering from NeP who met the
inclusion criteria as well as 19 pain-free volunteers were
enrolled. As shown in Table 2, both groups of patients
significantly differed from healthy volunteers in terms of
stress level and depressive symptomatology. No signifi-
cant differences were detected between the patient
groups regarding pain levels at rest and during motion,
as well as duration of pain (Table 2). Furthermore, statis-
tical analysis of the number of patients receiving anal-
gesic and coanalgesic medication revealed no significant
difference between the two groups (Table 3).
Differential blood count and quantification of CD4+ cells
We quantified the number of neutrophil granulocytes,
representing an essential part of the innate immune
system, as well as total lymphocytes and CD4+ T cells
as key players of the adaptive immune response. As
shown in Fig. 3, numbers of polymorphonuclear leuko-
cytes (CLBP: 57.1 ± 8.7 %, NeP: 58.4 ± 9.1 %, healthy
volunteers: 55.2 ± 9.0; n.s.), total lymphocytes (CLBP:
33.2 ± 6.9 %, NeP: 29.9 ± 7.6 %, healthy volunteers: 34.4
± 7.2; n.s.), and CD4+ T cells (CLBP: 44.1 ± 11.4 %, NeP:
41.7 ± 11.3 %, healthy volunteers: 44.5 ± 10.5; n.s.) did
not differ between patients suffering from CLBP, NeP,
or healthy volunteers.
Fig. 2 Exemplary illustration of P2X7 receptor expression. For quantitative analysis of the proportion of CD4+ cells (a) and P2X7R protein expression (b),
cells were stained with PerCP-labeled antihuman CD4 antibody and FITC-labeled antihuman P2X7R antibody. We separately analyzed each subgroup by
the mean fluorescence intensity (MFI) of P2X7R expression. Overlay histograms of representative results of P2X7R expression of one patient/healthy volunteer
are displayed in histograms
Table 1 RT-PCR assay characteristics and primer sequences
Gene Primer sequence
TBP-87 for 5′ GAACATCATGGATCAGAACAACA 3′
rev 5′ ATAGGGATTCCGGGAGTCAT 3′
SDHA-132 for 5′ GAGGCAGGGTTTAATACAGCA 3′
rev 5′ CCAGTTGTCCTCCTCCATGT 3′
P2RX7 Roche RealTime Ready Single Assay ID 106724
Table 2 Patients characteristics
Healthy CLBP NeP
Numbers 19 19 19
Age (years) 40 ± 11 47 ± 13 58 ± 13*
Female (%) 58 % 79 % 68 %
BMI (kg/m2) 23.6 ± 2.9 23.9 ± 3.1 24.6 ± 3.8
Duration of pain
(years)
0.0 ± 0.0 5.9 ± 4.2* 4.5 ± 2.8*
NRS (rest) 0.0 ± 0.0 3.5 ± 2.2* 5.1 ± 2.2*
NRS (motion) 0.0 ± 0.0 4.4 ± 2.1* 6.9 ± 2.1*
KAB 1.7 ± 0.7 3.4 ± 0.9* 3.3 ± 0.9*
CES-D 2.4 ± 2.2 21.8 ± 7.3* 21.0 ± 9.6*
Patients with either CLBP or NeP significantly differed from healthy volunteers
in terms of duration of pain, NRS, KAB, and CES-D. However, no significant
differences were detected between CLBP and NeP patients for any of the
parameters. Data are presented as mean ± SD, n = 19, *p < 0.05 versus healthy
in paired Student’s t test (NeP) and Mann-Whitney Rank Sum Test (CLBP)
BMI body mass index; NRS (rest/motion) numeric rating scale (0–10) of pain, 0:
“no pain,” 10: “worst pain imaginable,” KAB questionnaire for self-perceived stress
ranging from 1 (no stress) to 6 (max. stress), CES-D center for epidemiologic
studies depression scale, CLBP chronic low back pain, NeP neuropathic pain
(symmetrical polyneuropathy, peripheral mononeuropathy, postherpetic
neuralgia, orofacial pain)
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P2RX7 mRNA expression is increased in patients with
NeP, but not in CLBP
The relative expression of P2RX7 mRNA was determined
by qPCR. Compared to healthy volunteers, significantly
elevated mRNA levels (1.6-fold) were detected in patients
with NeP (NeP: 1.6 ± 0.6, healthy volunteers 1.0 ± 0.3, p
< 0.05; Fig. 4), while only a mild increase of P2RX7
mRNA expression (1.1-fold) was found in patients with
CLBP (CLBP: 1.1 ± 0.6, healthy volunteers 1.0 ± 0.3, n.s.;
Fig. 4).
P2X7R protein expression is significantly increased on
lymphocytes and monocytes of patients with NeP
Consistent with the results on mRNA expression,
FACS results (MFI) revealed that compared to healthy
volunteers, P2X7R protein expression levels on lym-
phocytes (NeP: 21.8 ± 6.5, healthy volunteers: 15.6 ±
5.2; p = 0.009; Fig. 5a) and monocytes (NeP: 24.6 ± 6.2,
healthy volunteers: 17.0 ± 5.4; p = 0.002; Fig. 5d) were
significantly enhanced in patients with NeP, but not in
patients with CLBP. This P2X7R upregulation was de-
tected on both CD4+ monocyte (NeP: 21.0 ± 6.4,
healthy volunteers: 13.2 ± 4.8; p < 0.001; Fig. 5b) and
CD4− monocyte (NeP: 21.5 ± 6.5, healthy volunteers:
16.6 ± 4.9; p = 0.039; Fig. 5d) cells.
Differential IL-1β levels in patients with neuropathic pain
and CLBP
In a number of preclinical studies, IL-1β has been shown
to be mainly involved in neurodegeneration, inflamma-
tion, and pain [1, 10] and to be a key mediator of the
P2X7R-pain interplay. In order to find out whether the
observed differences in P2X7R expression between pa-
tients with CLBP and NeP are also reflected by IL-1β,
we analyzed serum levels of this pro-inflammatory and
pro-nociceptive cytokine by multiplex enzyme-linked
immunoassay. Concomitant with the P2X7R elevation,
we found significantly increased serum levels of IL-1β
(1.4-fold) only in the peripheral blood of patients suffer-
ing from neuropathic pain (Fig. 6).
Confounding analyses
Since P2X7R expression has been associated with vari-
ous diseases, we tested a set of potentially confounding
variables for significant differences in distribution be-
tween healthy volunteers and patients [24, 25]. As ele-
vated receptor expression is associated with depression
and anxiety, we tested the CES-D depression scores and
KAB values. Healthy volunteers showed significantly lower
depression and stress scores, but no differences were
Table 3 Patients’ medication at the beginning of the study
Medication at beginning of the study CLBP (n = 19) NeP (n = 19)
Ibuprofen (no. (%)) 3 (16) 2 (11)
Diclofenac (no. (%)) 2 (11) 3 (16)
Paracetamol (no. (%)) 3 (16) 2 (11)
Metamizole (no. (%)) 1 (5) 1 (5)
Opioids (no. (%)) 2 (11) 3 (16)
Pregabalin (no. (%)) 0 (0) 1 (5)
Duloxetine (no. (%)) 0 (0) 1 (5)
There is no significant difference in the intake of analgesics or coanalgesics in
patients with CLBP and NeP. Data are presented as mean ± SD, n = 19,
statistical testing was performed using Fisher’s exact test
CLBP chronic low back pain; NeP neuropathic pain (symmetrical




















































































Fig. 3 Differential blood count and quantification of CD4+ cells. In order to avoid misinterpretation of potentially elevated P2X7R protein expression
based on different cell counts, we quantified numbers of polymorphonuclear leukocytes (a), lymphocytes (b), and CD4+ cells (c). No differences were
found between patients suffering from CLBP, NeP, and healthy volunteers. Data are presented as mean ± SD, n = 19, *p < 0.05 in one-way ANOVA with
multiple comparisons versus healthy volunteers (Holm-Sidak method)
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found between patients with nociceptive and neuropathic
pain. Age differed significantly between patients and
healthy volunteers. However, a potential confounding effect
was excluded by investigating the correlation between age
and P2X7R levels (no significant correlation for both, Pear-
son’s and Spearman’s correlation test; r = 0.18, p = 0.16 and
rho = 0.17, p = 0.18, respectively), as well as checking
P2X7R levels in age-matched subgroups that yielded simi-
lar results as the main analysis. Moreover, no correlation
was found regarding gender and receptor expression.
Subgroup analysis of neuropathic pain syndromes revealed




In this study, we found a significantly increased expres-
sion of P2X7R mRNA and protein in lymphocytes and
monocytes as well as higher IL-1β serum levels in
patients suffering from NeP, but not in those with noci-
ceptive CLBP. These results might point to an import-
ant role of P2X7R and IL-1β in the pathogenesis and
maintenance of NeP.
Chronic pain is a global health problem, affecting up to
60 % of the population [26]. Over the last years, significant
effort has been made to investigate endogenous pain-
modulating factors [27]. In various animal models of
nociceptive, inflammatory, and neuropathic pain, the en-
dogenous receptor P2X7 was the focus of interest [2–5].
Recent data indicate that nociceptive information from
the periphery to the CNS is transmitted through various
ion channels and receptor pathways [28, 29]. The ATP-
sensitive P2X7R, which is particularly localized on im-
mune and microglial cells, is part of this reporter system
[29]. In response to inflammation or cellular damage, ATP
activates P2X7R, which represents an important step in
the transmission of sensory information to the central
nervous system [4, 30]. Recent studies suggest that
P2X7R is involved in the pathogenesis of neurological
disorders such as epilepsy, stroke, neuralgia, multiple
sclerosis, Alzheimer’s disease, Parkinson’s disease, and
Huntington’s disease [31]. Moreover, the P2X7R is asso-
ciated with mood disorders like major depression or
anxiety [31, 32]. Upon activation, P2X7R triggers a
series of physiological events that culminate in the
posttranscriptional processing and release of IL-1β
from monocytes [10]. IL-1β is a pro-inflammatory and
pro-nociceptive cytokine which was shown to be a key
mediator in chronic pain [33]. In addition, there is in-
creasing evidence that enhanced release of IL-1β after
P2X7R activation antagonizes morphine analgesia and
accounts for the development of morphine tolerance,
which may partly explain the insufficient effect of opi-
oids in a considerable number of NeP patients [34]. IL-
1β induces the transcription of cyclo-oxygenase 2
(COX-2) and nitric oxide synthase (iNOS), which play a
central role in the generation and maintenance of pain
[35, 36]. Within clinical settings, the efficacy of agents
to treat neuropathic pain is variable. While COX-2 in-
hibitors are particularly effective against the inflamma-
tory component of neuropathic pain, their effect on the
intensity of pain is generally not satisfactory [37]. Con-
trary, antiepileptic drugs and antidepressants are useful
to modulate the intensity of pain, but rather inefficient
to treat the inflammatory component [38]. P2X7R and IL-
1β are known to modulate inflammation and nociception,
which recently led to the discovery of pharmacological
agents selectively blocking P2X7R [30]. Genetic modula-







































Fig. 4 P2RX7 mRNA expression is exclusively increased in patients
with neuropathic pain. To confirm the flow cytometric observations
with elevated P2X7R protein expression, predominantly on CD4+
cells and only in NeP, we determined the relative P2RX7 mRNA
expression of CD4+ cells by qPCR. Affirmatively, increased mRNA
levels were consistent with the flow cytometric analyses and
exclusively elevated in patients with NeP. (p = 0.038). *p < 0.05. Data
are presented as mean ± SD, n = 19, *p < 0.05 in one-way ANOVA
with multiple comparisons versus healthy volunteers
(Holm-Sidak method)
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regression of symptoms in animal models of neurological
disorders and reduces the intensity of inflammatory and
neuropathic pain in mice [4, 39, 40].
These findings are consistent with our results dem-
onstrating an increased expression of lymphocyte and
monocyte P2X7R and IL-1β in patients suffering from
NeP. It is not surprising, that only slight elevations of
P2X7R protein, P2RX7 mRNA expression and of IL-1β
levels were found in patients with CLBP, as CLBP is
usually not associated with significant immune activation.
These findings might point to a minor role of the P2X7R/
IL-1β interplay in the pathophysiology of CLBP. This as-
sumption is supported by recent research, showing a com-
munication link between the immune system and the
CNS [1, 15]. Lesion of a peripheral nerve leads to both a
transition of microglia to the side of damage and an infil-
tration of immune cells in the vicinity of the synapse be-
tween primary afferent fibers and nociceptive neurons in
the dorsal horn of the spinal cord [41, 42]. These activated
immune cells release many pro-inflammatory mediators,
such as IL-1β which cross the blood-brain barrier [15] and
modulate pain intensity [40, 43]. A crucial regulator of
IL-1β release is P2X7R [10]. Peripheral knock-down of
P2X7R in mice leads to a significant decrease of IL-1β
release and reduction of pain intensity [40].
Since elevated P2X7R expression has also been associ-
ated with mood disorders such as depression and anxiety,
we tested the CES-D depression scores and KAB values as
potentially confounding variables. Healthy volunteers had
significantly lower depression and stress scores than both
patient subgroups, but no differences were found between
patients suffering from CLBP or NeP. In order to exclude
further factors being responsible for the different expres-
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Fig. 5 P2X7R expression on lymphocytes (a), CD4+ (b) and CD4− cells (c), and monocytes (d) is elevated in patients with neuropathic pain.
PBMCs were stained with PerCP-labeled antihuman CD4 antibody and FITC-labeled antihuman P2X7R antibody and analyzed by FACS. The results
show a significantly elevated P2X7R expression only in patients suffering from neuropathic pain on the analyzed cell type (lymphocytes (p = 0.009),
CD4+ cells (p < 0.001), CD4− cells (p = 0.039), and monocytes (p = 0.002)). Data are presented as mean ± SD, n = 19, *p < 0.05 in one-way ANOVA with
multiple comparisons versus healthy volunteers (Holm-Sidak method)
Fig. 6 IL-1β levels are elevated in patients with neuropathic pain. As
IL-1β was shown to be the key mediator in P2X7R-pain interplay, we
analyzed serum levels of this pro-inflammatory and pro-nociceptive
cytokine by multiplex immune assay. Affirmatively to the results with
elevated P2X7Rs, we solely found significant increased serum levels in
the peripheral blood of patients with NeP *p < 0.05. Data are presented
as mean ± SD, n = 19, *p < 0.05 in one-way ANOVA with multiple
comparisons versus healthy volunteers (Holm-Sidak method)
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confounder-analyses. Although age differed between
patients and healthy volunteers, a potential confound-
ing effect could be excluded. Furthermore, we found
that gender did not correlate with the expression of
P2X7R or IL-1β either. Regarding subgroups of NeP, no
differences with respect to the P2X7R expression were
found between patients suffering from peripheral poly-
neuropathy/mononeuropathy, postherpetic neuralgia or
orofacial pain. One limitation of our study is that the
analysis of P2X7R protein and mRNA expression was
performed on lymphocytes, whereas IL-1β levels were
determined in the peripheral blood. Since P2X7R is also
expressed on the surface of other immune cells such as
macrophages, which are also a major source of IL-1β
production, further studies are needed to clearly define
the source of elevated IL1β levels. Furthermore, it
would be interesting to take the monocytes followed by
LPS priming and ATP challenge to demonstrate differ-
ent IL-1β release between groups.
Conclusions
In conclusion, we here report that, in patients with NeP,
P2X7R expression is significantly elevated. Activation of
P2X7 has been shown to result in IL-1β release. Thus,
based on our data, we propose the hypothesis that in-
creased P2X7R expression leads to increased IL-1β blood
levels, which may either predispose or maintain neuro-
pathic pain. This P2X7R-driven inflammatory component
seems to be absent in patients with CLBP. Our results
suggest a major role of the purinergic-receptor/cytokine-
interplay in NeP and may help identify patients who might
benefit from P2X7R modulating treatment approaches.
Abbreviations
BMI: body mass index; CES-D scale: center for epidemiologic studies
depression scale; CLBP: chronic low back pain; CNS: central nervous system;
COX-2: cyclo-oxygenase 2; CRP: C-reactive protein; FACS: fluorescent-
activated cell sorting; FSC: forward scatter; IL: interleukine; iNOS: nitric oxide
synthase; KAB: Kurzfragebogen zur aktuellen Beanspruchung;
LC: lymphocytes; MC: monocytes; MFI: mean fluorescence intensity;
NeP: neuropathic pain; NRS: numerical rating scale; P2XR: purinergic P2X
receptor; PBMC: peripheral blood mononuclear cell; RT-PCR: quantitative
real-time PCR (qPCR); SD: standard deviation; SDHA: succinate
dehydrogenase complex subunit A; SSC: side scatter; TBP: TATA box
binding protein; Treg: regulatory T cell.
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